Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PRMT5 lactylation mediates SIRT6-dependent DNA damage and senescence in benzene-induced hematotoxicity. | Food Chem Toxicol | 2026 | 42612745 | PubTator, text mining | PubMed |
| PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer. | EMBO Mol Med | 2026 | 42608565 | PubTator, text mining | PubMed |
| Design and synthesis of the first PARP1 and PRMT5 dual inhibitors for the treatment of breast cancer. | Eur J Med Chem | 2026 | 42607456 | PubTator, text mining | PubMed |
| m6A-dependent regulation of DGUOK-AS1 by RBM15 and HNRNPH1 in lung adenocarcinoma. | iScience | 2026 | 42603931 | PubTator, text mining | PubMed |
| Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers. | J Med Chem | 2026 | 42593918 | PubTator, text mining | PubMed |
| A novel small molecule inhibitor targeting KHSRP methylation suppresses colon cancer progression. | Acta Pharm Sin B | 2026 | 42592425 | PubTator, text mining | PubMed |
| PPM1B suppresses cervical carcinoma invasion by dephosphorylating MYPT1 at Thr853 and inactivating the PRMT5 epigenetic axis. | Eur J Cell Biol | 2026 | 42585950 | PubTator, text mining | PubMed |
| Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. | Cancer Res Commun | 2026 | 42585676 | PubTator, text mining | PubMed |
| Discovery of PRMT5 Inhibitors from Semiliquidambar Cathayensis Chang Using Computational and Bioactivity Evaluation. | Curr Med Chem | 2026 | 42576532 | PubTator, text mining | PubMed |
| Exploring the BICC1 Interactome in HEK293T Cells: Insights Into RNA-Mediated Protein Networks and Biomolecular Condensates. | FASEB Bioadv | 2026 | 42569767 | PubTator, text mining | PubMed |
| Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer. | Eur J Med Chem | 2026 | 42566881 | PubTator, text mining | PubMed |
| Targeting PRMTs with small-molecule inhibitors: a comprehensive review. | RSC Med Chem | 2026 | 42549137 | PubTator, text mining | PubMed |
| A highly selective 1,2-dihydroquinoxaline derivative as a potent PRMT5-MTA complex inhibitor. | Bioorg Med Chem | 2026 | 42541959 | PubTator, text mining | PubMed |
| Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers. | Bioorg Chem | 2026 | 42531724 | PubTator, text mining | PubMed |
| The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer. | Clin Cancer Res | 2026 | 42507545 | PubTator, text mining | PubMed |
| G3BP1 methylation by PRMT5 facilitates its recruitment of TBK1 for IRF3 activation during host response to foreign ribonucleic acids. | Front Immunol | 2026 | 42488687 | PubTator, text mining | PubMed |
| Protein arginine methyltransferases as regulators of phase separation: implications in cancer and neurodegenerative diseases. | Eur Biophys J | 2026 | 42484672 | PubTator, text mining | PubMed |
| Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC. | Sci Rep | 2026 | 42477403 | PubTator, text mining | PubMed |
| Targeting the PRMT5/Nur77 methylation axis enhances endometrial decidualization capacity and female fertility in preclinical models. | J Clin Invest | 2026 | 42467593 | PubTator, text mining | PubMed |
| Immunohistochemical Loss of MTAP as a Diagnostic and Prognostic Surrogate of CDKN2A/B Homozygous Deletion: A Narrative Review. | Diagnostics (Basel) | 2026 | 42449850 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=2